CardioGene Therapeutics
This article was originally published in Start Up
Executive Summary
Gene Therapy; Cardiovascular; Restenosis. CardioGene has a patented method of promoting gene expression in vascular smooth muscle cells and endothelial cells. The technology also incorporates a double balloon catheter for delivery of the product to theinner wall of the blood vessel. CardioGene also has nine patent applications that include the use of adenovirus vectors to carry genes to vascular smooth muscle cells and means of coating stents with recombinant DNA.
You may also be interested in...
Restenosis: Multi-Billion-Dollar Market Tempts Many
A variety of approaches are being used to combat the problem of restenosis following angioplasty. In addition to separate drug and device efforts, several companies are working on drug-device collaborations to prevent restenosis.
polyGenomics Inc.
PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.
Oxagen Ltd.
Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.